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Abstract
PURPOSE—To assess whether porosity and compressibility of calibrated spherical polyvinyl
alcohol (PVA) microspheres affect doxorubicin plasma and tumor concentrations after transcatheter
arterial chemoembolization (TACE) in a VX2 rabbit model.
MATERIALS AND METHODS—Fifteen rabbits were divided into three groups of five rabbits
each. Three different types of calibrated spherical PVA microspheres with variable levels of porosity
and compressibility were blindly evaluated. TACE was performed by injecting a mixture of
doxorubicin (5 mg) and iodized oil (0.5 mL) followed by injection of the embolic material (0.3–0.5
mL). Plasma concentrations of doxorubicin and doxorubicinol were analyzed 20, 40, 60, and 120
minutes and 2 days after TACE, and liver tissue and tumor doxorubicin concentrations were measured
2 days after TACE.
RESULTS—All calibrated spherical PVA microspheres showed similar patterns of plasma
doxorubicin and doxorubicinol release and tumor concentration of doxorubicin. There were no
significant differences of drug levels in either plasma or tumor in each group (P > .05).
CONCLUSIONS—After TACE in a rabbit model of liver cancer, testing of three different types of
spherical PVA microspheres with varying degrees of porosity and compressibility showed no
significant differences in the plasma doxorubicin release pattern and tumor doxorubicin uptake.
Transcatheter arterial chemo-embolization (TACE) has become the mainstay of palliative
therapy for most primary and secondary unresectable hepatic malignancies (1–3). The
technique consists of delivering high concentrations of chemotherapeutic agents emulsified in
iodized oil to the tumor bed followed by embolization. The blockage of arterial inflow by using
embolic material is an important step in TACE because it allows the prolonged stasis of
chemotherapeutic agents inside the tumor, which may then decay according to their half-life.
Currently, the most commonly used embolic agents are gelatin absorbable sponge pledgets
(4,5), a temporary embolic material, and polyvinyl alcohol (PVA) particles (6) and tris-acryl
gelatin microspheres (7,8), both of which are permanent embolic agents. A recent study testing
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for the arterial distribution of calibrated tris-acryl gelatin and PVA microspheres showed that
the repartition of a spherical embolic agent in an arterial lumen could be influenced by its size
as well as by its deformation within the arterial lumen (9). That is, the degree of porosity and
compressibility that is directly related to the deformation of microspheres and their distribution
within the arterial lumen seems to be an important character of microspheres.
In this study, we are focusing on one spherical microsphere composition and one size range
with three different degrees of porosity and compressibility and their performance in affecting
the stasis of a chemotherapeutic agent within the VX2 liver tumor model.
MATERIALS AND METHODS
Our institution′s Animal Care and Use Committee approved the study, and all animal care and
procedures were performed under institutional guidelines.
Animal and Tumor Model
Adult New Zealand White male rabbits weighing 3.8–4.3 kg (Myrtle′s Rabbitry, Thompson
Station, Tennessee) were used. Fifteen rabbits were divided into three groups of five rabbits
each for the study of three different types of spherical PVA microspheres. A commercially
available PVA microsphere was used as an embolic material in one group, and two different
prototypes were used in the others. Although the VX2 tumor is of non-hepatic origin, it has
proved to be a convenient animal model of liver cancer due to its rapid growth and similarity
in blood supply to that of human hepatocellular carcinoma.
Anesthesia and Analgesia
A mixture of 2.5 mg/kg acepromazine (Phoenix, St Joseph, Missouri) and 44 mg/kg ketamine
hydrochloride (Phoenix) was injected intramuscularly before TACE. Intravenous access was
secured via a marginal ear vein, and 0.1–0.2 mL (2.5–5 mg) of sodium pentobarbital (Hospira,
Lake Forest, Illinois) was administered intravenously periodically to maintain anesthesia.
When performing TACE, endotracheal intubation with a 3.0-mm endotracheal tube
(Mallinkrodt Medical, St Louis, Missouri) was performed to monitor end-tidal CO2. After the
surgery, analgesic buprenorphine (0.02–0.05 mg/kg) was injected intramuscularly for pain
control.
Tumor Implantation
To obtain solid tumors for implantation, VX2 tumor cell suspension (~1 × 107 cells, 200 µL)
was injected into both thigh muscles of a carrier rabbit. Two weeks later, the bulk of solid
tumors were harvested from the carrier rabbit by means of surgical excision of tumor-bearing
muscle and put into 0.9% sodium chloride. The abdomen of each recipient rabbit was shaved
and prepared in a sterile fashion. The liver was exposed with a midline subxiphoid incision
and the left lateral lobe pulled out. Then, a small incision of the liver capsule and parenchyma
at the implantation site was made and adequate space created to insert an approximately 3-
mm3 single piece of harvested tumor. The incised capsule was approximated and compressed
manually. After the absence of bleeding was confirmed, the exposed liver was repositioned
into its original peritoneal space. The abdomen was closed in two layers with aseptic technique.
The tumors were allowed to grow for another 13–15 days, at which time they were sufficiently
large and well demarcated.
Embolic Material
Three different spherical PVA microspheres (Contour SE, Boston Scientific, Natick,
Massachusetts; and prototypes A and B, Boston Scientific/Oncology Division, Marlborough,
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Massachusetts) were labeled with different codes and tested blindly. The microspheres were
produced by means of a previously published process (10). The characteristics of the
microspheres and scanning electron microscope (SEM) images are shown in the Table and
Figure 1, respectively. These spherical PVA microspheres were of the same size range (100–
300 µm) and chemical composition and produced with the same technological process. The
manufacturing process was modified to introduce various levels of porosity to the micro-
spheres in each group. This was accomplished by varying the ratio of PVA to gelling agent.
Although it was not possible to quantify the differences in compressibility for microspheres
of this size, the correlation between porosity and compressibility has been described previously
(9), where it was reported that more porous embolic microspheres compressed more and
penetrated to more distal locations compared with nonporous materials of equivalent size. We
therefore presumed that the differences in porosity, as measured with SEM imaging, resulted
in different levels of compressibility for each group. The amount of particles was 1 mL in 5
mL of solution. This volume was then diluted with an equal volume of contrast medium
(Omnipaque; Amersham, Piscataway, New Jersey).
TACE
Access to the right common femoral artery was performed by means of surgical cut-down. A
3.5-F sheath (Cook, Bloomington, Indiana) was then slowly inserted, followed by a 2-F catheter
with a tip in the shape of a hockey stick (JB1 catheter; Cook), which was first advanced into
the aorta and then into the celiac trunk and common hepatic artery. Arteriography of the
common hepatic artery demonstrated the hepatic arterial anatomy and the location, size, and
vascularity of the tumor. Then, the 2-F JB1 catheter was advanced over the 0.014-inch guide
wire (Transend; Boston Scientific/Medi-tech, Miami, Florida) and into the tumor feeding
artery. The mixture of doxorubicin (Bedford Laboratories, Bedford, Ohio; 5 mg) and iodized
oil (Ethiodol, 0.5 mL; Savage Laboratories, Melville, New York) was injected, followed by
embolization with spherical PVA microspheres (0.3–0.5 mL) until flow reduction was
observed. After the embolic material was injected, the catheter and sheath were removed and
the common femoral artery was ligated with absorbable sutures.
Plasma Concentrations of Doxorubicin/Doxorubicinol
After TACE, whole blood samples (5 mL) were collected to assay plasma concentrations of
doxorubicin and doxorubicinol (a metabolite of doxorubicin) at various time points (20, 40,
60, and 120 minutes and 2 days). Whole blood samples were placed on ice and centrifuged
within 3.5 hours with 2,000 rpm for 10 minutes at room temperature. Isolated plasma was
frozen at −20°C until the time of analysis.
Euthanasia and Tumor Doxorubicin Concentration
Two days after TACE, rabbits were euthanized under deep anesthesia by means of slow
intravenous injection of a lethal dose (100 mg per 5 mL) of sodium pentobarbital. Liver tissue
was obtained immediately after euthanasia. Careful dissection of tumor was performed from
explanted liver, and two tumor pieces were cut—one from the tumor core and one from the
tumor periphery. Nontumorous liver tissue from the left medial and right lobes was also
obtained to check for nontargeted drug deposition. All tissue samples were immediately placed
on dry ice and frozen at −80°C until the time of analysis. Analysis was performed with atomic
absorption spectroscopy.
Statistics
The plasma and tissue doxorubicin concentrations for all groups were compared with the
Student t test. Differences were considered statistically significant at P < .05.
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RESULTS
Plasma Doxorubicin/Doxorubicinol
Plasma levels of doxorubicin and doxorubicinol in each group measured at 20, 40, 60, and 120
minutes and 2 days after TACE are shown in Figure 2 and Figure 3. Drug levels were
undetectable 2 days after TACE. All spherical PVA microspheres showed similar patterns of
plasma doxorubicin and doxorubicinol release without statistically significant differences (P
> .05).
Tumor Doxorubicin Concentrations
The intratumoral doxorubicin concentrations in each group measured at euthanasia are shown
in Figure 4. All spherical PVA microspheres showed a similar pattern of doxorubicin
concentration inside the tumor without statistically significant differences (P > .05).
Doxorubicin concentration at the nontargeted left medial lobe and the right lobe of the liver
was undetectable (<0.6 nmol/g).
DISCUSSION
The goal of TACE is to deliver large amounts of chemotherapeutic agents to the tumor via the
tumor feeding artery. Apparently, additional embolization after the administration of the
mixture of chemotherapeutic agent and iodized oil is desirable in most clinical practices. To
that end, several types of embolic materials are used to reduce arterial inflow, which
subsequently decelerates drug washout and maximizes contact time between the drug and the
tumor cells. The first embolic agent to be employed for this purpose was gelatin absorbable
sponge pledgets. Raoul et al (4) first showed that additional embolization with gelatin
absorbable sponge particles, after the injection of the mixture of doxorubicin and iodized oil,
reduced doxorubicin plasma concentration and significantly increased its intratumoral
concentration. However, the problem with gelatin absorbable sponge pledgets is that their size,
which is made by hand cut, is large and unpredictable, most likely leading to proximal
obstruction and the development of revascularization of treated lesions through aberrant
collateral vessels and, therefore, limiting the efficacy of further embolization. Nonspherical
PVA particles were next introduced into clinical practice (11). PVA particles seem to have a
more controllable effect than gelatin sponge, as their smaller size allows deeper penetration
and more permanent vessel occlusion. Their irregular shape, however, does not ensure product
uniformity and may result in unpredictable catheter or vessel occlusion (12–15). In a study
comparing nonspherical PVA and one type of spherical microspheres (Embosphere, Biosphere
Medical, Rockland, Massachusetts) (8), doxo-rubicin concentration in the tumor was found to
be greater in the Embosphere group than in the nonspherical PVA group. Although the clinical
evidence of such results remains to be supported, the authors suggest that TACE with calibrated
spherical microspheres may be more beneficial than nonspherical PVA because of the greater
concentration of drug present within the tumor.
The aim of our study was to assess for differences in doxorubicin plasma and intratumoral
concentrations among calibrated spherical microspheres of a similar size range. Because the
arterial distribution of microspheres of the same size may depend on porosity and
compressibility (9), we assumed that more distal embolization that may be achieved with more
compressible microspheres may impede collateral circulation more efficiently and allow less
washout of the chemotherapeutic agent. We therefore expected to see differences in plasma
and intratumoral doxorubicin concentrations among the three tested types of spherical PVA
microspheres. Our results, however, did not show any significant differences in plasma and
intratumoral drug concentrations among the tested microspheres. These results could be
explained due to the special inherent characteristics of iodized oil. Iodized oil may act as both
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an embolic agent and a drug carrier, leading to embolization and drug deposition at the level
of the intratumoral capillaries. Moreover, the injected volume of iodized oil has been shown
to affect the total amount of injected chemotherapy (6,16). Our results could also be explained
due to the endothelial damage and subsequent arterial spasm generated by the injected toxic
chemotherapeutic agent. It has been demonstrated that porosity and compressibility affect the
injectability and injectable amount of spherical microspheres through a catheter; however, in
our study, it was hard to detect differences in injectability among the three tested types of
spherical PVA microspheres because the preceding iodized oil injection and the arterial spasm
caused by the toxic chemotherapeutic agent had already created a significant reduction in
arterial inflow.
In conclusion, after TACE in the VX2 liver rabbit model, there were no significant differences
in the doxorubicin plasma and intratumoral concentrations among three different PVA
microspheres with a similar size range, despite their varying degrees of porosity and
compressibility.
Abbreviations
PVA, polyvinyl alcohol; TACE, transcatheter arterial chemoembolization.
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Figure 1.
Images from cross-section scanning electron microscopy of Contour SE (a), prototype A (b),
and prototype B (c) microspheres. Contour SE is the most compressible microsphere, followed
by prototype B and prototype A. The Contour SE microsphere exhibits large macropores
distributed in the microsphere center surrounded by a microporous structure toward the exterior
surface (arrows in a). The number and size of macropores decreases in prototype B (arrows in
c), whereas prototype A (b) shows no macropores.
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Figure 2.
Graph shows plasma doxorubicin levels at sequential time points after TACE.
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Figure 3.
Graph shows plasma doxorubicinol levels at sequential time points after TACE.
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Figure 4.
Bar chart shows doxorubicin concentration in tumor 2 days after TACE.
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Characteristics of Three Spherical PVA Microspheres
Characteristics
Group 1
(Contour SE)
Group 2
(Prototype A)
Group 3
(Prototype B)
Mean particle diameter (µm) 275 ± 90 269 ± 58 278 ± 66
Sphericity ~0.90 0.93 0.94
Porosity/compressibility Most Least Intermediate
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